Hemostemix Inc
- LAST PRICE0.0850
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.0850/ 125
- Ask / Lots0.0850/ 84
- Open / Previous Close--- / 0.0850
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Oct 31, 2024
Hemostemix Announces the First Tranche Closing of $1.8M of Its Recently Announced Private Placement, from 4:05PM ET on Thursday Oct 31, 2024 by Dow Jones
4:05PM ET on Thursday Oct 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Hemostemix Inc | 10.5M | -4.0x | --- |
Telo Genomics Corp | 8.9M | -3.2x | --- |
XORTX Therapeutics Inc | 5.5M | -37.3x | --- |
Marvel Biosciences Corp | 7.6M | -3.2x | --- |
Glow Lifetech Corp | 6.7M | -1.6x | --- |
GeneTether Therapeutics Inc | 3.9M | -4.7x | --- |
Company Information
Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.
Contact Information
- Headquarters
- 707 7th Ave. SW, Suite 1150CALGARY, AB, Canada T2P 3H6
- Phone
- 905-580-4170
- Fax
- 403-818-7672
Executives
- Independent Chairman of the Board
- Peter Lacey
- President, Chief Executive Officer, Director
- Thomas Smeenk
- Interim Chief Financial Officer
- Christina Wu
- Independent Director
- Ronnie Hershman
- Independent Director
- Loran Swanberg
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $10.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 124.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.17 |
EPS | $-0.02 |
Book Value | $-0.08 |
P/E Ratio | -4.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
